{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:00:14Z","timestamp":1776168014885,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["114TTMHH-TMUH-04"],"award-info":[{"award-number":["114TTMHH-TMUH-04"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010792","name":"Tungs' Taichung MetroHarbor Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007750","name":"National Cheng Kung University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jiph.2026.103212","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:03:45Z","timestamp":1773968625000},"page":"103212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Linezolid-associated adverse events and outcomes in the treatment of multidrug\/rifampicin-resistant tuberculosis: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1085-5742","authenticated-orcid":false,"given":"Mita","family":"Restinia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-9018","authenticated-orcid":false,"given":"Fajri","family":"Gafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-6298","authenticated-orcid":false,"given":"Wen-Hsuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-8908","authenticated-orcid":false,"given":"Chung-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103212_bib1","unstructured":"WHO. Global Tuberculosis Report. 2024. Available at \u3008https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024\u3009. Accessed 1 July 2025."},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib2","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","article-title":"Drug resistant TB - latest developments in epidemiology, diagnostics and management","volume":"124","author":"Tiberi","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.jiph.2026.103212_bib3","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1016\/S2214-109X(21)00299-0","article-title":"Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis","volume":"9","author":"Silva","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5588\/ijtld.14.0078","article-title":"Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention","volume":"19","author":"Reid","year":"2015","journal-title":"Int J Tube Lung Dis"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12913-019-4429-y","article-title":"Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon - a qualitative study exploring the experiences and perceptions of patients and healthcare professionals","volume":"19","author":"McNally","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.jiph.2026.103212_bib6","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1016\/S2214-109X(23)00160-2","article-title":"Addressing the adherence challenge in tuberculosis treatment: more than digital technologies","volume":"11","author":"Jiang","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jiph.2026.103212_bib7","unstructured":"WHO. Consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment, 2022 update. 2022."},{"issue":"10","key":"10.1016\/j.jiph.2026.103212_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jiph.2026.103212_bib9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jiph.2026.103212_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"25","key":"10.1016\/j.jiph.2026.103212_bib11","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jiph.2026.103212_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425255.2016.1166204","article-title":"Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones","volume":"12","author":"Cattaneo","year":"2016","journal-title":"Expert Opin Drug Metab & Toxicol"},{"issue":"2","key":"10.1016\/j.jiph.2026.103212_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-022-03446-4","article-title":"Linezolid pharmacokinetics: a systematic review for the best clinical practice","volume":"79","author":"Heidari","year":"2023","journal-title":"Eur J Clin Pharm"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.jiph.2026.103212_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index","volume":"14","author":"Wasserman","year":"2016","journal-title":"Expert Rev AntiInfect Ther"},{"issue":"2","key":"10.1016\/j.jiph.2026.103212_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4046\/trd.2021.0122","article-title":"Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria","volume":"85","author":"Oehadian","year":"2022","journal-title":"Tube Respir Dis"},{"issue":"6","key":"10.1016\/j.jiph.2026.103212_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"mBio"},{"issue":"11","key":"10.1016\/j.jiph.2026.103212_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.jiph.2026.103212_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3855\/jidc.18366","article-title":"Risk factors for linezolid - induced haematological toxicity in patients: a retrospective study","volume":"18","author":"Mo","year":"2024","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"10.1016\/j.jiph.2026.103212_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00315-2025","article-title":"Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"66","author":"Kwak","year":"2025","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jiph.2026.103212_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tube Lung Dis"},{"issue":"6","key":"10.1016\/j.jiph.2026.103212_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jiph.2026.103212_bib23","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10.1016\/j.jiph.2026.103212_bib25","first-page":"Cd012836","article-title":"Linezolid for drug-resistant pulmonary tuberculosis","volume":"3","author":"Singh","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.jiph.2026.103212_bib26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","article-title":"Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Lifan","year":"2019","journal-title":"Int J Tube Lung Dis"},{"issue":"3","key":"10.1016\/j.jiph.2026.103212_bib27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jiph.2026.103212_bib28","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"10362","key":"10.1016\/j.jiph.2026.103212_bib29","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103212_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2022.03.020","article-title":"Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for patients with postoperative multidrug-resistant spinal tuberculosis","volume":"118","author":"Qiao","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-024-03633-3","article-title":"Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China","volume":"22","author":"Song","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jiph.2026.103212_bib32","doi-asserted-by":"crossref","unstructured":"Conradie F., Badat T., Poswa A., Rajaram S., Kooverjee S., Maartens G., et al. BEAT Tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis. medRxiv. 2025;2025.05.04.25326549. https:\/\/doi.org\/10.1101\/2025.05.04.25326549.","DOI":"10.1101\/2025.05.04.25326549"},{"issue":"2","key":"10.1016\/j.jiph.2026.103212_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf020","article-title":"New all-oral short-term regimen for multidrug-resistant tuberculosis: a semi-randomized controlled trial conducted in China","volume":"12","author":"Jing","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jiph.2026.103212_bib34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib35","first-page":"6822","article-title":"Study on the effectiveness and safety of linezolid dose reduction in multidrug-resistant tuberculosis","volume":"11","author":"Shukla","year":"2025","journal-title":"Int J Life Sci"},{"issue":"25","key":"10.1016\/j.jiph.2026.103212_bib36","first-page":"00194","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"S2213-2600","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiph.2026.103212_bib37","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2026.103212_bib38","author":"WHO","year":"2014","journal-title":"Companion Handb WHO Guidel Programma Manag DrugResist Tuberc"},{"key":"10.1016\/j.jiph.2026.103212_bib39","unstructured":"WHO\u00a0Consol Guidel Tuberc Modul 4 Treat DrugResist Tuberc Treat\u00a02024. Available at.\u00a0\u3008https:\/\/www.who.int\/publications\/i\/item\/9789240063129\u3009(https:\/\/www.who.int\/publications\/i\/item\/9789240063129\u3009. Accessed 18 Nov 2025."},{"issue":"4","key":"10.1016\/j.jiph.2026.103212_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkq017","article-title":"Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"65","author":"Anger","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103212_bib41","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2026.103212_bib42","unstructured":"Higgins J.P.T. Thomas J. Chandler J. Cumpston M. Li T. Page M.J. et al. Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). 2024. Available from www.cochrane.org\/handbook."},{"issue":"8","key":"10.1016\/j.jiph.2026.103212_bib43","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/sim.10008","article-title":"Sensitivity analysis with iterative outlier detection for systematic reviews and meta-analyses","volume":"43","author":"Meng","year":"2024","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.jiph.2026.103212_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4097\/kja.20637","article-title":"Trial sequential analysis: plain and simple","volume":"74","author":"De Cassai","year":"2021","journal-title":"Korean J Anesth"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ije\/31.1.88","article-title":"Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy","volume":"31","author":"Song","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jiph.2026.103212_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083864","article-title":"Core GRADE 4: rating certainty of evidence\u2014risk of bias, publication bias, and reasons for rating up certainty","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jiph.2026.103212_bib47","article-title":"Clinical trial of linezolid in treatment of multi drug resistant tuberculosis at public sector Hospital Lahore","volume":"13","author":"Tabassum","year":"2019","journal-title":"PJMHS"},{"issue":"1","key":"10.1016\/j.jiph.2026.103212_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiph.2026.103212_bib49","unstructured":"WHO. Guidance on evidence generation on new regimens for tuberculosis treatment. 2021. Available at: \u3008https:\/\/www.who.int\/publications\/i\/item\/9789240103627\u3009. Accessed 18 Nov 2025."},{"issue":"8","key":"10.1016\/j.jiph.2026.103212_bib50","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"10S","key":"10.1016\/j.jiph.2026.103212_bib51","doi-asserted-by":"crossref","first-page":"S2469","DOI":"10.14309\/01.ajg.0000965084.67178.6e","article-title":"rare case of linezolid-induced acute liver failure","volume":"118","author":"Chokshi","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jiph.2026.103212_bib52","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/08998280.2020.1855922","article-title":"Linezolid use and drug-induced liver injury","volume":"34","author":"Shaikh","year":"2020","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1016\/j.jiph.2026.103212_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1551062","article-title":"The protective role of vitamin C against linezolid-induced hepato-renal toxicity in a rat model","volume":"16","author":"Azzam","year":"2025","journal-title":"Front Pharm"},{"issue":"S1","key":"10.1016\/j.jiph.2026.103212_bib54","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130","author":"Vanino","year":"2023","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:14:38Z","timestamp":1776165278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034126000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1876034126000845"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103212","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linezolid-associated adverse events and outcomes in the treatment of multidrug\/rifampicin-resistant tuberculosis: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103212"}}